iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (BTEK)

Category Sector Equity Biotechnology

This ETF can be held in an Investment ISA, SIPP and Investment Account

Sell

£5.4225

Buy

£5.4425

arrow-down£-0.04375 (-0.80%)

Prices updated at 13 Nov 2024, 15:04 GMT

Prices minimum 15 mins delay

Prices in GBP

Investment objective

The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.

FTSE All-Share

-0.01%

LSE

Important notice: This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Please refer to the FCA website which details further information in relation to sustainability disclosure requirements for retail clients.

Important documents: Please ensure that you have read the Key Information Document/Technical Guide , Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.

Annual charges

Product charges
	0.35
	0.02
Minimum investment	25.00

Documents

Document name	Date posted	Download
Fund Provider FactSheet	12 Nov 2024	pdf
Annual Reports	31 May 2024	pdf
Annual Short Report	31 May 2024	pdf
Key Information Document / Technical Guide	29 Jan 2024	pdf
Interim Short Report	30 Sep 2023	pdf

Please note that service charges will also apply. Read more about our fees.

Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Any ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.